
Goldline Pharmaceutical IPO
- Issue price
- ₹43
- Listing price
- ₹59.75
- +38.95%
- Current price
- ₹29.27
- -31.93%
- Subscribed
- 781.85x
- Issue size
- ₹12 Cr
- Listed on
- 19 May 2026
IPO timeline
- Opens12 MayTue
- Closes14 MayThu
- Allotment15 MayFri
- Refunds18 MayMon
- Demat credit18 MayMon
- Listing19 MayTue
Issue details
- Price band
- ₹41 – ₹43 per share
- Issue size
- ₹12 Cr
- Fresh issue
- ₹12 Cr · 0.28 Cr shares
- Offer for sale
- None
- Issue type
- Fresh capital only
- Face value
- ₹10 per share
- Lot size
- 3,000 shares
- Minimum investment
- ₹1,29,000
- Listing on
- BSE SME
- Exchange code
- GLPL.BO · 7716
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 3,000 | ₹1,29,000 |
| Retail (Max) | 1 | 3,000 | ₹1,29,000 |
| HNI (Min) | 2 | 6,000 | ₹2,58,000 |
Reservation
- QIB
- 12,72,000 shares (49.65% of the Offer)
- NII
- 3,90,000 shares (15.22% of the Offer)
- Retail
- 9,00,000 shares (35.13% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on Bigshare Services- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 15 May 2026
- Refunds initiated
- 18 May 2026
- Shares credited to demat
- 18 May 2026
- Listing
- 19 May 2026
Grey market premium (GMP)
- Current GMP
- ₹15
- +35.00%
- Estimated listing price
- ₹58
- Issue price ₹43
- Highest
- ₹25
- 13 May
- Lowest
- ₹8
- 8 May
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 18 May 2026 | ₹15 | +35.00% | ₹58 |
| 17 May 2026 | ₹20 | +47.00% | ₹63 |
| 15 May 2026 | ₹18 | +42.00% | ₹61 |
| 14 May 2026 | ₹15 | +35.00% | ₹58 |
| 13 May 2026 | ₹25 | +58.00% | ₹68 |
| 12 May 2026 | ₹18 | +42.00% | ₹61 |
| 11 May 2026 | ₹17 | +40.00% | ₹60 |
| 10 May 2026 | ₹15 | +35.00% | ₹58 |
| 9 May 2026 | ₹8 | +19.00% | ₹51 |
| 8 May 2026 | ₹8 | +19.00% | ₹51 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB180.22x
- NII (HNI)1,227.9x
- Retail881.15x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 5,40,000 | 9,73,17,000 | 180.22x |
| Non-Institutional Investors (NII) | 5,28,000 | 64,83,33,000 | 1,227.9x |
| bNII — bids above ₹10 Lakh | 2,58,000 | 51,88,74,000 | 2,011.14x |
| sNII — bids ₹2 Lakh to ₹10 Lakh | 1,32,000 | 12,94,59,000 | 980.75x |
| Retail Individual Investors (RII) | 9,00,000 | 79,30,38,000 | 881.15x |
| Total | 19,68,000 | 1,53,86,88,000 | 781.85x |
Financials
- P/E Ratio
- 13.93
- EPS (₹)
- 3.09
- RoCE
- 38.45%
- RoNW
- 27.37%
- PAT Margin
- 10.09%
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 27.40 | 26.28 | 22.93 | 19.39 |
| Total Income | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| EBITDA | 4.16 | 5.83 | 4.30 | 2.19 |
| NET Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserves and Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Goldline Pharmaceutical This IPO | ₹12 Cr | 13.93 | 27.37% | 10.09% | 781.85x | +38.95% |
| Himalaya Nutravedics India SME · listed 29 Sep 2026 | ₹26.5 Cr | 12.63 | 45.12% | 17.16% | 2.24x | +11.32% |
| Speciality Medicines SME · listed 30 Mar 2026 | ₹29 Cr | 10.49 | 28.30% | 14.77% | 2.19x | 0.00% |
| Avience Biomedicals SME · listed 25 Jun 2026 | ₹30.24 Cr | 16.56 | 49.89% | 15.86% | 385.4x | +90.00% |
| ABH Healthcare SME · listed 1 Sep 2026 | ₹34.98 Cr | 20.69 | 39.07% | 10.74% | 1.42x | -2.94% |
| Bio Medica Laboratories SME · listed 29 May 2026 | ₹52 Cr | 13.45 | 99.59% | 25.64% | 2.31x | -20.00% |
| Pramodini Medicare SME · listed 19 Aug 2026 | ₹69.04 Cr | 14.97 | 32.69% | 27.90% | 3.66x | +1.69% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Goldline Pharmaceutical plans to use the money raised, as stated in the offer document.
- Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company₹8.9 Cr
- General corporate purposes
About Goldline Pharmaceutical
Goldline Pharmaceutical Limited was established in 2005 and is engaged in the marketing and distribution of pharmaceutical formulations across India. The company has built its presence through a wide portfolio of healthcare products catering to multiple therapeutic segments. Over the years, Goldline has expanded its distribution network and strengthened relationships with doctors, distributors, and healthcare professionals. The company is promoted by experienced industry professionals who focus on expanding the brand presence and improving market reach in the domestic pharmaceutical sector. The company offers products across general medicine, antibiotics, cardiology, diabetology, gynecology, pediatrics, and wellness categories. Goldline Pharmaceutical mainly follows an asset-light business model, where manufacturing is outsourced to third-party pharma manufacturers while the company focuses on branding, marketing, and distribution activities. This model helps reduce capital expenditure and improve scalability. The company’s operations are mainly based in Nagpur, Maharashtra, with a growing presence across multiple Indian states through its marketing and sales network.
Strengths
- Asset-light business model reduces manufacturing costs and improves operational scalability significantly.
- Diversified pharmaceutical portfolio caters to multiple therapeutic and healthcare treatment segments.
- Strong doctor and distributor network supports consistent product demand across regions.
- Experienced promoters with pharmaceutical industry knowledge help drive business expansion plans.
Risks
- Dependence on third-party manufacturers may impact product quality and timely supply.
- Highly competitive pharmaceutical industry can pressure margins and market share growth.
- Revenue concentration in domestic markets increases dependence on Indian pharmaceutical demand.
- Regulatory changes in healthcare sector may affect operations and product approvals.
- Smaller business scale compared to major pharma companies limits competitive advantages currently.
Promoters and shareholding
Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal
- Promoter holding, pre-issue
- 79.70
- Promoter holding, post-issue
- 57.29%
Registrar, lead managers and documents
Lead manager
Company contact
103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, 440015
+91 712 2786666
info@goldlinepharma.inGoldline Pharmaceutical IPO: common questions
1.When does the Goldline Pharmaceutical IPO open and close?
The Goldline Pharmaceutical IPO opens on 12 May 2026 and closes on 14 May 2026.
2.What is the price band of the Goldline Pharmaceutical IPO?
The price band is ₹41 – ₹43 per share, with a lot size of 3,000 shares and a minimum investment of ₹1,29,000.
3.What is the size of the Goldline Pharmaceutical IPO?
The issue size is ₹12 Cr (Fresh capital only).
4.What is the GMP of the Goldline Pharmaceutical IPO?
The last reported grey market premium is ₹15 per share as of 18 May 2026, 05:31 PM IST. GMP is unofficial and changes frequently.
5.When is the Goldline Pharmaceutical IPO allotment?
The basis of allotment is expected on 15 May 2026. Allotment status can be checked with the registrar, Bigshare Services Private Limited.
6.When will the Goldline Pharmaceutical IPO list?
The shares listed on 19 May 2026 on BSE SME.
7.Who is the lead manager of the Goldline Pharmaceutical IPO?
The book running lead manager is Cumulative Capital Pvt. Ltd., and the registrar is Bigshare Services Private Limited.
8.What will the money raised in the Goldline Pharmaceutical IPO be used for?
As stated in the offer document, the proceeds are for: Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company; General corporate purposes.
9.How can my company launch an IPO like Goldline Pharmaceutical?
Start with an IPO readiness assessment: eligibility for the NSE Emerge or BSE SME platform, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393